ArticleBMC psychiatry2022
Burden of schizophrenia among Japanese patients: a cross-sectional National Health and Wellness Survey.
Article in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Associations between depressive symptoms and work productivity loss in patients with schizophrenia: an observational 48-week longitudinal study.BMC psychiatry · 2026Observational
- Dysmenorrhea patients' experience with work productivity impact and treatment in Japan.BMC women's health · 2026Article
- Clinical, social, and economic burdens of schizophrenia in Japan: a targeted literature review.Schizophrenia (Heidelberg, Germany) · 2026Review
- Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan.Frontiers in psychiatry · 2026Article
- Assessment of Social Functioning in Patients With Schizophrenia and Their First-Degree Relatives.Journal of clinical medicine research · 2026Article
- Adaptation of the "Osnabrück Scale for Therapy Adjustment and Identification of Psychological Complaints in Schizophrenia-OSSTI-TR" into Turkish culture and investigation of its psychometric characteristics.Frontiers in psychiatry · 2026Article
- Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: aFrontiers in psychiatry · 2026Article
- Estimating the Prevalence of Schizophrenia in the General Population of Japan Using an Artificial Neural Network-Based Schizophrenia Classifier: Web-Based Cross-Sectional Survey.JMIR formative research · 2025Article
- Clinical effectiveness of paliperidone palmitate 3-monthly and 1-monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database.Neuropsychopharmacology reports · 2024Article
- Analysis of human neuronal cells carrying ASTN2 deletion associated with psychiatric disorders.Translational psychiatry · 2024Article
- Sex Differences in the Relationship Between Schizophrenia and the Development of Cardiovascular Disease.Journal of the American Heart Association · 2024Article
- Cost-effectiveness of interferon-Epidemiology and infection · 2024Article
- Factors associated with death, hospitalization, resignation, and sick leave from work among patients with schizophrenia in Japan: a nested case-control study using a large claims database.BMC psychiatry · 2024Article
- Temporal trends in antipsychotic prescriptions for pediatric patients using an administrative hospital database in Japan: a retrospective study.Journal of pharmaceutical health care and sciences · 2024Article
- Structure/function interrelationships and illness insight in patients with schizophrenia: a multimodal MRI data fusion study.European archives of psychiatry and clinical neuroscience · 2023Article
- Association of Low-Normal Free T4 Levels With Future Major Depression Development.Journal of the Endocrine Society · 2023Article
- Physical, Psychiatric, and Social Comorbidities of Individuals with Schizophrenia Living in the Community in Japan.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia places a great humanistic and financial burden to patients, families, and societies, and the burden is substantially impacted by comorbid conditions. This study aimed to estimate the lifetime prevalence of schizophrenia and to assess the health-related quality of life (HRQoL), work productivity, and indirect cost among schizophrenia patients with and without comorbidities (depressive symptoms, sleep disturbances, and anxiety problems).
methodsThis is a secondary analysis of existing data collected in 2019 from the Japan National Health and Wellness Survey. The schizophrenia patients were categorized based on their Patient Health Questionnaire-9 score, self-reported experience of sleep disturbances, and anxiety problems. The lifetime prevalence was estimated using the total number of diagnosed schizophrenia patients as the numerator and the total number of respondents as the denominator. The HRQoL was evaluated through the Short Form 12-Item (version 2) Health Survey and EuroQoL 5-dimensions scale. Work productivity and annual indirect costs were evaluated through the Work Productivity and Activity Impairment instrument and monthly wage rates. Multivariate analyses included the comparison of outcomes using generalized linear models.
resultsThe study was conducted with 178 schizophrenia patients with an average age of 42.7 years old and an estimated lifetime prevalence of 0.59% (95% CI: 0.51%, 0.68%). Patients who experienced sleep disturbances, more severe depressive symptoms, and anxiety problems had lower HRQoL, higher levels of absenteeism, presenteeism, total work productivity and activity impairment, and almost twice more indirect costs, compared to those without these conditions.
conclusionComorbid conditions among patients with schizophrenia impact significantly on their quality of life, work productivity as well as indirect costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.